Skip to content
biosimilar development

Biosimilars, Biologics, FDA Policy and Approvals, Clinical Trials, and Specialty Pharmacy

  • Home
    • Home
  • About BR&R
  • Biosimilar Approval Status
  • BR&R Product Profiles
    • Abrilada
    • Amjevita
    • Avasola
    • Cyltezo
    • Erelzi
    • Eticovo
    • Fulphila
    • Hadlima
    • Herzuma
    • Hulio
    • Hyrimoz
    • Inflectra
    • Kanjinti
    • Mvasi
    • Nivestym
    • Nyvepria
    • Ogivri
    • Ontruzant
    • Renflexis
    • Retacrit
    • Ruxience
    • Trazimera
    • Truxima
    • Udenyca
    • Zarxio
    • Ziextenzo
    • Zirabev
  • Contact Us
  • The 2021 Biosimilars Market Report
  • $0.00 0 items

Cart

Your cart is currently empty.

Return to shop

ACI Meeting 2021

Recent Posts

  • Today’s Supreme Court Decision Saves the US Biosimilar Regulatory Framework June 17, 2021
  • Bending the Reference Biologic Price Curve June 15, 2021
  • Tanvex BioPharma Receives Complete Response Letter on Its Filgrastim Biosimilar Application June 9, 2021
  • Lupin’s Pegfilgrastim Biosimilar 351(k) Application Being Evaluated by FDA June 8, 2021
  • Are Biosimilars and the Oncology Care Model a Perfect Fit? June 4, 2021
  • Biosimilar Education for Healthcare Professionals June 1, 2021
  • Biosimilar Bytes May 18, 2021
  • Switching Study Complete, Biosimilar Maker Awaits FDA Decision on Interchangeability May 3, 2021
  • Further Dissecting the Launch of Adalimumab Biosimilars in the US April 21, 2021
  • Is Identification of Biosimilars vs. Reference Products Still an Issue? April 20, 2021

Recent Comments

steven miller on Today’s Supreme Court De…
Today's Supreme… on Will the Supreme Court Fast Fo…
Bending the Referenc… on What Will Cost Savings on 2023…
Biosimilar Education… on Transition Day for Insulins, O…
Biosimilar Bytes | B… on Further Dissecting the Launch…

Archives

Meta

  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Top Posts & Pages

  • Today's Supreme Court Decision Saves the US Biosimilar Regulatory Framework
  • Biosimilar Approval Status
  • The Evolution of the Biosimilars Market
  • Who Are the Key Aflibercept Biosimilar Players to Watch?
  • Who Are the Key Lucentis Biosimilar Players to Watch?
  • Denosumab Biosimilar Competitors Gathering Data for February 2025 Launch
  • A Profile of a Lesser-Known Player in the Biosimilar Space: Alvotech
  • Abrilada
  • Ruxience
  • Amgen Settles With Alexion on Soliris Biosimilar, Dropping Litigation and Getting a Release Date
Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookie Policy

Follow Us

  • Twitter
  • LinkedIn
  • Home
  • About BR&R
  • Biosimilar Approval Status
  • Contact Us
  • Terms and Conditions

Copyright

Copyright 2013-2021 by SM Health Communications. All Rights Reserved

Powered by WordPress.com.